SLShan Li

Shan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shan Li has a total of 142 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Zhang

    MOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, PR China

    9 shared publications
  • Jufang Wang

    South China University of Technology

    8 shared publications
  • Lei Zhang

    MOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, PR China

    7 shared publications
  • Jing Li

    MOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, PR China

    4 shared publications
  • Cheng-Xi Cao

    School of Automation and Intelligence Sensing, Shanghai Jiao Tong University, Shanghai, 200240, China

    3 shared publications
  • Ji Liu

    School of Bioscience & Bioengineering, South China University of Technology, Guangzhou 510006, China

    3 shared publications

Latest Publications

  • Open Access

    Development of a Whole-Cell Bioprocess for Ursodeoxycholic Acid Production from Lithocholic Acid Using Fusarium equiseti HG18

    by Yao Yan, Xinyi Mao, Fen Liu, Shan Li

    Ursodeoxycholic acid (UDCA) is the first-line therapy for primary biliary cholangitis and an important active constituent of bear bile. Whole-cell microbial conversion of inexpensive lithocholic acid (LCA) offers a promising alternative to conventional chemical synthesis owing to its high regioselectivity and mild reaction conditions, yet the fermentation process of Fusarium equiseti HG18 (CCTCC M2023160), a natural fungal catalyst for LCA 7β-hydroxylation, has not been systematically engineered for scalable production. This study developed a whole-cell process for UDCA production by F. equiseti HG18. Systematic optimization by single-factor experiments, Plackett–Burman design and Box–Behnken response surface methodology raised the shake-flask UDCA titer from 0.19 to 0.59 mg mL−1. Scale-up in a 3 L stirred-tank bioreactor shortened the fermentation time from 144 h in shake-flask cultivation to 96 h in the bioreactor under optimized operating conditions (pH 8.5, aeration 2.5 L min−1, and agitation 200 rpm). Experiments across a range of initial LCA loadings revealed a progressive decline in UDCA molar yield at elevated substrate concentrations, consistent with substrate-related inhibitory effects, and this loading-dependent behavior was used to design a two-stage fed-batch feeding strategy. Under the optimized condition (2.0 mg mL−1 LCA fed at 0 and 48 h), UDCA titer reached 1.71 mg mL−1, corresponding to a volumetric productivity of 17.8 mg L−1 h−1 and a UDCA molar yield of 41%. This study establishes a laboratory-scale whole-cell bioprocess for UDCA production from LCA using a wild-type fungal catalyst, integrating statistical medium optimization, bioreactor process development, and substrate-feeding strategies. The findings provide a practical framework for improving fungal whole-cell steroid biotransformation and highlight the potential of wild-type fungal platforms for scalable biocatalytic production.

  • Enhanced Regioselectivity and Catalytic Activity on C7Hydroxylation of Lithocholic Acid to Produce Ursodeoxycholic Acid by Monooxygenase CYP107D1 Based on Semi‐Rational Design

    by Ci Song, Xiaomin Zheng, Zhenru Zhou, Yundong Yu, Lei Zhang, Shan Li

    Ursodeoxycholic acid (UDCA), a natural bile acid, is widely utilized in treating hepatobiliary disorders due to its ability to reduce bile concentration and protect liver function. While the CYP107D1 (OleP) triple‐mutant F84Q/S240A/V291G is the first identified bacterial monooxygenase capable of directly converting lithocholic acid (LCA) to UDCA via C7β‐hydroxylation, its industrial application has been hindered by low catalytic efficiency. The study implemented a semi‐rational design strategy combined with a cell‐free enzyme catalysis method, utilizing the OleP triple mutant as a template, to screen for mutants with enhanced 7β‐hydroxylation activity. The superior quadruple‐mutant G294A/N236H/F321W/V297A was engineered through iterative combinatorial mutagenesis, which catalyzed the production of about 0.68 mM UDCA from 1 mM substrate LCA. This variant exhibited a 50% increase in catalytic activity and a 40% improvement in regioselectivity compared to the template OleP triple‐mutant. Molecular docking and kinetic simulations further demonstrated that the quadruple mutant stabilized the enzyme‐substrate complex through optimized binding interactions, thereby enhancing catalytic proficiency. Our findings elucidate critical structural determinants governing C7‐hydroxylation of LCA.


  • Metronidazole-ursodeoxycholic acid bifunctional antibacterial: A promising strategy to combat Clostridium difficile infection and prevent recurrence

    by Kun Shi, Li Wang, Xiao-Min Zheng, Zhe Zhang, Fan Zhong, Zhen-Zhu Sun, Mohamed Mohany, Hai-Hui Huang, Jing Li, Shan Li, et al.


  • Open Access

    A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo

    by Junmin Li, Yanting Zhou, Zhuowei Su, Xue Li, Lei Zhang, Shan Li

    Cell-penetrating peptides (CPPs) are invaluable tools for delivering various substances into cells by crossing biological membranes. However, the effects of cell-penetrating peptide fusion proteins on the biological activity of antibodies remain to be fully understood. Here, we engineered a recombinant protein, LP-scFv, which combines the single-chain variable region of anti-human epidermal growth factor receptor-2 with a novel and non-oxic cell-penetrating peptide as a leader peptide. The introduction of this leader peptide led to a more than twofold increase in the internalization efficiency of the single-chain antibody, as confirmed using microscopic analysis and flow cytometry. The effects of the single-chain antibodies and LP-scFv on cell viability were evaluated using the MTT assay. Both the single-chain antibodies and LP-scFv reduced the viability of BT474 and NCI-N87 cells in a dose-dependent manner while exhibiting minimal toxicity towards MCF-7 and MCF-10A cells. Further investigation into LP-scFv’s mechanism revealed that the induced leader peptide does not alter the MAPK-ERK1/2 and PI3K/AKT pathways of single-chain antibodies. An enhanced antitumor activity was also confirmed in an NCI-N87 tumor xenograft model in mice with a reduction of 45.2% in tumor growth inhibition (vs. 23.1% for scFv) with a 50 mg/kg dose after orthotopic injection administration, which was equivalent to that of trastuzumab (vs. 55.7% for trastuzumab). Overall, these results indicate that LP-scFv exhibits significant permeation activity in HER2-positive cells to enhance the intracellular dose effect on antitumor activity in vitro and in vivo. This research lays the foundation for designing novel antibody-based therapies for cancer.


  • Open Access

    Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway

    by Xing-Yang Shi, Xiao-Min Zheng, Hui-Jie Liu, Xue Han, Lei Zhang, Bei Hu, Shan Li

    Background: Steatosis and inflammation are the hallmarks of nonalcoholic steatohepatitis (NASH). Rotundic acid (RA) is among the key triterpenes of Ilicis Rotundae Cortex and has exhibited multipronged effects in terms of lowering the lipid content and alleviating inflammation. The study objective is to systematically evaluate the potential mechanisms through which RA affects the development and progression of NASH. Methods: Transcriptomic and proteomic analyses of primary hepatocytes isolated from the control, high-fat diet-induced NASH, and RA treatment groups were performed through Gene Ontology analysis and pathway enrichment. Hub genes were identified through network analysis. Integrative analysis revealed key RA-regulated pathways, which were verified by gene and protein expression studies and cell assays. Results: Hub genes were identified and enriched in the Toll-like receptor 4 (TLR4)/activator protein-1 (AP1) signaling pathway and glycolysis pathway. RA reversed glycolysis and attenuated the TLR4/AP1 pathway, thereby reducing lipid accumulation and inflammation. Additionally, lactate release in L-02 cells increased with NaAsO2-treated and significantly decreased with RA treatment, thus revealing that RA had a major impact on glycolysis. Conclusions: RA is effective in lowering the lipid content and reducing inflammation in mice with NASH by ameliorating glycolysis and TLR4/AP1 pathways, which contributes to the existing knowledge and potentially sheds light on the development of therapeutic interventions for patients with NASH.


  • Regio‐ and stereo‐selective 1β‐hydroxylation of lithocholic acid by cytochrome P450 BM3 mutants

    by Haiyan Li, Wei Dai, Shuaishuai Qin, Shan Li, Yundong Yu, Lei Zhang

    Regio‐ and stereo‐selective hydroxylation of bile acids is a valuable reaction but often lacks suitable catalysts. In the research, semi‐rational design in protein engineering techniques had been applied on cytochrome P450 monooxygenase CYP102A1 (P450 BM3) from Bacillus megaterium, and a mutation library had been set up for the 1β‐hydroxylation of lithocholic acid (LCA) to produce 1β‐OH‐LCA. After four rounds of mutagenesis, a key residue at W72 was identified to regulate the regio‐ and stereo‐selectivity at C1 of LCA. A quadruple variant (G87A/W72T/A74L/L181M) was identified to reach 99.4% selectivity of 1β‐hydroxylation and substrate conversion of 68.1% resulting in a 21.5‐fold higher level of 1β‐OH‐LCA production than the template LG‐23. Molecular docking indicated that introducing hydrogen bonds at W72 was responsible for enhancing selectivity and catalytic activity, which gave some insights into the structure‐based understanding of Csp3‐H activation by the developed P450 BM3 mutants.


  • Open Access

    RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant

    by Jianing Yang, Xuejiao Hu, Wenzhuo Wang, Yujing Yang, Xinqiang Zhang, Wei Fang, Lei Zhang, Shan Li, Bing Gu

    The highly infectious Delta variant strain of SARS-CoV-2 remains globally dominant and undermines COVID-19 vaccines. Rapid detection of the Delta variant is crucial for the identification and quarantine of infected individuals. In this study, our aim was to design and validate a genotyping RT-LAMP method to detect Delta variants specifically. R203M in the N gene of SARS-CoV-2 was chosen as the Delta variant-specific mutation for genotyping. To target the R203M-harboring region and the conserved sequence of the N gene, two sets of primers were designed, and a Cq (quantification cycle) ratio-based RT-LAMP for SARS-CoV-2 and R203M detection was developed by analyzing the significant discrepancy in amplification efficiency of the two sets of primers. We validated the RT-LAMP method on 498 clinical specimens in parallel with RT-qPCR, and 84 Delta variants from 198 positive samples were determined by sequencing. Compared with traditional RT-qPCR analyses, RT-LAMP appears to be 100% accurate in detecting SARS-CoV-2 clinical samples. RT-LAMP has a good ability to distinguish between Delta and non-Delta variants under a Cq ratio threshold of 1.80. Furthermore, the AUC (area under the curve) of this method was 1.00; the sensitivity, specificity and accuracy were all 100%. In summary, we have proposed a rapid, accurate and cost-effective RT-LAMP method to detect SARS-CoV-2 and Delta variants, which may facilitate the surveillance of COVID-19.